Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2026 10:46 ET | Source: Quetzal Therapeutics

QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration...
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
November 12, 2025 14:21 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Appoints Todd Smith as Board Member

Quetzal Therapeutics Appoints Todd Smith as Board Member
September 16, 2025 12:10 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer

Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer
July 16, 2025 13:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.